Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data demonstrating that its lead candidate, Telomir-Zn, suppresses tumor growth in prostate and triple-negative breast cancer (TNBC) models through selective modulation of intracellular iron and copper. The findings, published in the Journal of Oncology Research and Therapy, provide the scientific foundation for advancing Telomir-Zn into a planned Phase 1/2 clinical trial in TNBC under the company's active Investigational New Drug (IND) application.
The study revealed that Telomir-Zn inhibits histone demethylases by depleting intracellular iron, selectively killing iron-dependent TNBC cells while sparing normal cells at concentrations more than 50-fold higher. Additionally, it reactivated tumor-suppressor genes in a prostate cancer model. In TNBC xenograft models, Telomir-Zn reduced primary tumor size across several cell lines and significantly reduced metastatic dissemination in HCC1806 xenografts. Notably, in BT-549 xenografts, combining Telomir-Zn with paclitaxel produced significantly greater tumor reduction than either treatment alone, while MDA-MB-231 xenografts did not respond, indicating tumor-specific differences in sensitivity.
These results are particularly significant given the aggressive nature of triple-negative breast cancer, which accounts for approximately 10-15% of all breast cancers and has limited treatment options compared to other subtypes. The selective mechanism of action—targeting cancer cells' reliance on iron while sparing healthy cells—could offer a novel therapeutic approach with a favorable safety profile. The ability of Telomir-Zn to enhance the efficacy of paclitaxel, a standard chemotherapy agent, also suggests potential for combination strategies that could improve patient outcomes.
The publication in a peer-reviewed journal adds credibility to the preclinical findings, which are often scrutinized in the oncology community. Peer review ensures that the data have been evaluated by independent experts, reducing the risk of bias and increasing confidence in the results. This is a critical step before moving to human trials, as it validates the scientific rationale and provides a stronger basis for regulatory discussions and investor confidence.
Telomir Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. Telomir-Zn is designed to modulate intracellular metal homeostasis and epigenetic regulation, and it has received IND clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. The company's focus on this difficult-to-treat cancer highlights its commitment to addressing high unmet medical needs.
For more information, visit the full press release at https://ibn.fm/mv3hn and the company's newsroom at https://ibn.fm/TELO.
